Table 2.
Base case results, per treated patient with confirmed CNS infection
| IMI/REL | CMS + IMI | Difference | |
|---|---|---|---|
| Health outcomes | |||
| Clinical cure | 79.0% | 52.0% | 27.0% |
| In-hospital mortality | 15.2% | 39.0% | − 23.8% |
| Nephrotoxicity | 14.6% | 56.4% | − 41.8% |
| QALY | 7.20 | 10.91 | 3.7 |
| Cost outcomes | |||
| Antibiotic treatment | $12,339 | $2519 | $9821 |
| Hospital resource | $81,551 | $91,439 | − $9888 |
| Adverse events | $4375 | $15,524 | − $1149 |
| Long-term monitoring | $410 | $283 | $127 |
| Total cost | $98,675 | $109,765 | − $11,090 |
| Cost-effectiveness | |||
| ICER, $ per death averted | − $46,579 (Dominant*) | ||
| ICER, $ per nephrotoxicity averted | − $26,521 (Dominant) | ||
| ICER, $ per QALY | − $1988 (Dominant) | ||
CMS colistimethate sodium; ICER incremental cost-effectiveness ratio; IMI imipenem; LY life year; QALY quality-adjusted life year
*“Dominant” in cost-effectiveness analysis means that the new technology (IMI/REL in this study) incurs lower total cost while generating higher health outcomes relative to the existing technology (CMS + IMI in this study)